Trial Outcomes & Findings for Calcium Chloride for Prevention of Blood Loss During Intrapartum Cesarean Delivery (NCT NCT05027048)

NCT ID: NCT05027048

Last Updated: 2024-06-11

Results Overview

Standardized volumetric and gravimetric assessment of blood loss during cesarean. Note: will analyze all participants, but planned subgroup analysis will also occur excluding patients with non-atonic reasons for blood loss including hysterotomy extension, placental abruption, cervical or vaginal laceration, etc

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

120 participants

Primary outcome timeframe

measurement occurs at conclusion of operating room case

Results posted on

2024-06-11

Participant Flow

Participant milestones

Participant milestones
Measure
Calcium Chloride
1 gram of calcium chloride in total volume 60mL with sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Saline Placebo
60mL sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Overall Study
STARTED
60
60
Overall Study
COMPLETED
60
60
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Calcium Chloride for Prevention of Blood Loss During Intrapartum Cesarean Delivery

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Calcium Chloride
n=60 Participants
1 gram of calcium chloride in total volume 60mL with sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Saline Placebo
n=60 Participants
60mL sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Total
n=120 Participants
Total of all reporting groups
Age, Continuous
33.8 years
STANDARD_DEVIATION 5.2 • n=99 Participants
32.8 years
STANDARD_DEVIATION 5.2 • n=107 Participants
33.3 years
STANDARD_DEVIATION 5.2 • n=206 Participants
Sex: Female, Male
Female
60 Participants
n=99 Participants
60 Participants
n=107 Participants
120 Participants
n=206 Participants
Sex: Female, Male
Male
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race/Ethnicity, Customized
Asian
24 Participants
n=99 Participants
19 Participants
n=107 Participants
43 Participants
n=206 Participants
Race/Ethnicity, Customized
Hispanic or Latina
17 Participants
n=99 Participants
23 Participants
n=107 Participants
40 Participants
n=206 Participants
Race/Ethnicity, Customized
Non-hispanic black
0 Participants
n=99 Participants
2 Participants
n=107 Participants
2 Participants
n=206 Participants
Race/Ethnicity, Customized
Non-hispanic white
16 Participants
n=99 Participants
12 Participants
n=107 Participants
28 Participants
n=206 Participants
Race/Ethnicity, Customized
Other or declines to state
3 Participants
n=99 Participants
4 Participants
n=107 Participants
7 Participants
n=206 Participants
Body Mass index (kg/m^2)
31.6 kg/m^2
STANDARD_DEVIATION 4.6 • n=99 Participants
32.2 kg/m^2
STANDARD_DEVIATION 6.1 • n=107 Participants
31.9 kg/m^2
STANDARD_DEVIATION 5.4 • n=206 Participants
Gravida (n)
1 pregnancies
n=99 Participants
1 pregnancies
n=107 Participants
1 pregnancies
n=206 Participants
Para
0 Prior pregnancies
n=99 Participants
0 Prior pregnancies
n=107 Participants
0 Prior pregnancies
n=206 Participants
Gestational age (completed weeks)
39 completed weeks
n=99 Participants
39 completed weeks
n=107 Participants
39 completed weeks
n=206 Participants
Advanced maternal age (n, %)
28 Participants
n=99 Participants
18 Participants
n=107 Participants
46 Participants
n=206 Participants
Hypertension from all causes (n, %)
7 Participants
n=99 Participants
17 Participants
n=107 Participants
24 Participants
n=206 Participants
Preeclampsia (n, %)
4 Participants
n=99 Participants
7 Participants
n=107 Participants
11 Participants
n=206 Participants
Diabetes, all causes (n, %)
7 Participants
n=99 Participants
11 Participants
n=107 Participants
18 Participants
n=206 Participants
Asthma (n, %)
3 Participants
n=99 Participants
7 Participants
n=107 Participants
10 Participants
n=206 Participants
Multiple gestation (n, %)
1 Participants
n=99 Participants
1 Participants
n=107 Participants
2 Participants
n=206 Participants
Chorioamnionitis (n, %)
9 Participants
n=99 Participants
8 Participants
n=107 Participants
17 Participants
n=206 Participants
Trial of Labor after Cesarean (TOLAC) (n, %)
5 Participants
n=99 Participants
3 Participants
n=107 Participants
8 Participants
n=206 Participants
Indication: first stage arrest
31 Participants
n=99 Participants
30 Participants
n=107 Participants
61 Participants
n=206 Participants
Indication: second stage arrest
20 Participants
n=99 Participants
18 Participants
n=107 Participants
38 Participants
n=206 Participants
Indication: fetal intolerance of labor
16 Participants
n=99 Participants
18 Participants
n=107 Participants
34 Participants
n=206 Participants
Indication: failed operative vaginal delivery
1 Participants
n=99 Participants
3 Participants
n=107 Participants
4 Participants
n=206 Participants
Indication: maternal request
1 Participants
n=99 Participants
3 Participants
n=107 Participants
4 Participants
n=206 Participants
Indication: other
3 Participants
n=99 Participants
2 Participants
n=107 Participants
5 Participants
n=206 Participants
Maximum oxytocin dose in labor
11.7 milliunits per minute
STANDARD_DEVIATION 8.5 • n=99 Participants
12.4 milliunits per minute
STANDARD_DEVIATION 9.1 • n=107 Participants
12.1 milliunits per minute
STANDARD_DEVIATION 8.8 • n=206 Participants
Hours of oxytocin exposure during labor
16.3 hours
STANDARD_DEVIATION 12.0 • n=99 Participants
18.5 hours
STANDARD_DEVIATION 12.1 • n=107 Participants
17.4 hours
STANDARD_DEVIATION 12.1 • n=206 Participants

PRIMARY outcome

Timeframe: measurement occurs at conclusion of operating room case

Standardized volumetric and gravimetric assessment of blood loss during cesarean. Note: will analyze all participants, but planned subgroup analysis will also occur excluding patients with non-atonic reasons for blood loss including hysterotomy extension, placental abruption, cervical or vaginal laceration, etc

Outcome measures

Outcome measures
Measure
Calcium Chloride
n=60 Participants
1 gram of calcium chloride in total volume 60mL with sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Saline Placebo
n=60 Participants
60mL sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Quantitative Blood Loss
840 milliliters
Interval 650.0 to 1434.0
1051 milliliters
Interval 796.0 to 1395.0

SECONDARY outcome

Timeframe: operative course (within 4-6 hours of fetal delivery)

Postpartum hemorrhage was defined as quantitative blood loss \> 1000 milliliters during operative course

Outcome measures

Outcome measures
Measure
Calcium Chloride
n=60 Participants
1 gram of calcium chloride in total volume 60mL with sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Saline Placebo
n=60 Participants
60mL sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Number of Participants With Postpartum Hemorrhage
24 Participants
34 Participants

SECONDARY outcome

Timeframe: within 4 hours of delivery

Yes/no: did the patient require treatment with methylergonovine, carboprost, and/or misoprostol for uterine atony

Outcome measures

Outcome measures
Measure
Calcium Chloride
n=60 Participants
1 gram of calcium chloride in total volume 60mL with sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Saline Placebo
n=60 Participants
60mL sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Number of Participants With Second Line Uterotonic Requirement
18 Participants
24 Participants

SECONDARY outcome

Timeframe: 96 hours of delivery

Yes/no, if patient required transfusion of packed red blood cells prior to hospital discharge

Outcome measures

Outcome measures
Measure
Calcium Chloride
n=60 Participants
1 gram of calcium chloride in total volume 60mL with sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Saline Placebo
n=60 Participants
60mL sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Number of Patients With a Transfusion Requirement
5 Participants
9 Participants

SECONDARY outcome

Timeframe: 1 day

Measured pre-delivery hematocrit minus measured post-operative day 1 hematocrit. Correction factor of 3 hematocrit points per unit packed red blood cells transfused

Outcome measures

Outcome measures
Measure
Calcium Chloride
n=60 Participants
1 gram of calcium chloride in total volume 60mL with sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Saline Placebo
n=60 Participants
60mL sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Change in Hematocrit From Baseline
7.8 Percentage of hematocrit
Interval 6.6 to 9.2
9.6 Percentage of hematocrit
Interval 8.1 to 11.7

SECONDARY outcome

Timeframe: Cesarean duration, within 4-6 hours of fetal delivery

Population: Note: institutional standard policy is a 2 unit oxytocin bolus at the time of fetal delivery, with additional boluses prn

Total dose oxytocin bolus during cesarean

Outcome measures

Outcome measures
Measure
Calcium Chloride
n=60 Participants
1 gram of calcium chloride in total volume 60mL with sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Saline Placebo
n=60 Participants
60mL sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Total Oxytocin Bolus Requirement
3 units
Interval 2.0 to 4.0
3 units
Interval 2.0 to 4.0

SECONDARY outcome

Timeframe: 7 minutes after fetal delivery, 5 minutes after initiating study drug infusion

Uterine tone assessment: Obstetricians at the study institution use the following validated scale to grade uterine tone for all cesarean deliveries. The obstetrician places their hand directly on the uterine fundus and scores the adequacy of contraction. The interrater characteristics of this scale have been published (Cole et al, 2021). The scale ranges from 0-10. A score of 0 is the worst possible score and represents a flaccid, atonic uterus. A score of 10 is the best possible score and represents a firmly-contracted uterus.

Outcome measures

Outcome measures
Measure
Calcium Chloride
n=60 Participants
1 gram of calcium chloride in total volume 60mL with sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Saline Placebo
n=60 Participants
60mL sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Uterine Tone Numerical Rating Score, 7 Minutes After Fetal Delivery
7 units on a scale
Interval 6.0 to 8.0
6.5 units on a scale
Interval 6.0 to 7.0

SECONDARY outcome

Timeframe: 12 minutes after fetal delivery, 10 minutes after initiating study drug infusion

Uterine tone assessment: Obstetricians at the study institution use the following validated scale to grade uterine tone for all cesarean deliveries. The obstetrician places their hand directly on the uterine fundus and scores the adequacy of contraction. The interrater characteristics of this scale have been published (Cole et al, PMID 33652161). The scale ranges from 0-10. A score of 0 is the worst possible score and represents a flaccid, atonic uterus. A score of 10 is the best possible score and represents a firmly-contracted uterus.

Outcome measures

Outcome measures
Measure
Calcium Chloride
n=60 Participants
1 gram of calcium chloride in total volume 60mL with sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Saline Placebo
n=60 Participants
60mL sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Uterine Tone Numerical Rating Score, 12 Minutes After Fetal Delivery
7 units on a scale
Interval 6.0 to 8.0
7 units on a scale
Interval 6.0 to 8.0

SECONDARY outcome

Timeframe: Operating room duration, usually 2 hours

Total crystalloid required during cesarean delivery in mL

Outcome measures

Outcome measures
Measure
Calcium Chloride
n=60 Participants
1 gram of calcium chloride in total volume 60mL with sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Saline Placebo
n=60 Participants
60mL sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Fluid Requirement
1594 milliliters
Standard Deviation 762
1502 milliliters
Standard Deviation 892

SECONDARY outcome

Timeframe: every 5 minutes for 30 minutes after study drug infusion initiation, compared to baseline

Baseline mean arterial blood pressure recorded as average of first 6 mean arterial blood pressures recorded in operating room. Percent change calculated as measured mean arterial blood pressure minus baseline, divided by baseline. Reported here as the maximal decrease in mean arterial pressure. Repeated measures ANOVA reported in Statistical Analysis.

Outcome measures

Outcome measures
Measure
Calcium Chloride
n=60 Participants
1 gram of calcium chloride in total volume 60mL with sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Saline Placebo
n=60 Participants
60mL sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Percent Change in Mean Arterial Pressure
16 percent change
Interval 11.0 to 21.0
12 percent change
Interval 4.0 to 20.0

SECONDARY outcome

Timeframe: every 5 minutes for 30 minutes after study drug infusion initiation, compared to baseline

Baseline heart rate recorded as average of first 6 heart rates recorded in operating room. Percent change calculated as measured heart rate minus baseline, divided by baseline. Maximal % increase in heart rate reported here. Repeated measures ANOVA used to analyze overall trend in Statistical Analysis below.

Outcome measures

Outcome measures
Measure
Calcium Chloride
n=60 Participants
1 gram of calcium chloride in total volume 60mL with sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Saline Placebo
n=60 Participants
60mL sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Percent Change in Heart Rate From Baseline
0 percent change
Interval -4.0 to 5.0
10 percent change
Interval 4.0 to 15.0

SECONDARY outcome

Timeframe: Duration of operating room time, up to 240 minutes

Population: Total of documented phenylephrine bolus and infusion administration during operative course

Total phenylephrine in milligrams administered while in the operating room

Outcome measures

Outcome measures
Measure
Calcium Chloride
n=60 Participants
1 gram of calcium chloride in total volume 60mL with sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Saline Placebo
n=60 Participants
60mL sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Total Phenylephrine Requirement
1.02 milligrams
Interval 0.0 to 2.26
1.09 milligrams
Interval 0.08 to 2.72

SECONDARY outcome

Timeframe: In the operating room prior to study drug administration (generally <30 minutes prior to fetal delivery and study drug administration)

Population: A total of 35 trial participants consented to provide serial blood specimens for ionized calcium measurement and pharmacokinetic analysis, per protocol.

Measured using an Abbott istat machine and CG8+ cartridge to determine venous blood gas ionized calcium levels

Outcome measures

Outcome measures
Measure
Calcium Chloride
n=19 Participants
1 gram of calcium chloride in total volume 60mL with sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Saline Placebo
n=16 Participants
60mL sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Pharmacokinetics of Calcium Chloride - Baseline Ionized Calcium
1.15 mmoL / liter
Standard Deviation 0.02
1.16 mmoL / liter
Standard Deviation 0.03

SECONDARY outcome

Timeframe: At Tmax (conclusion of the 10-minute intravenous calcium chloride infusion

Population: Participants who participated in the nested pharmacokinetic study and were randomly assigned to the calcium chloride group.

Generated from a 2-compartment population pharmacokinetic model in NONMEM using serial venous blood gas ionized calcium concentrations.

Outcome measures

Outcome measures
Measure
Calcium Chloride
n=18 Participants
1 gram of calcium chloride in total volume 60mL with sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Saline Placebo
60mL sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Pharmacokinetics of Calcium Chloride - Peak Change in Ionized Calcium From 1 Gram of Calcium Chloride
0.39 mmoL / liter
Interval 0.37 to 0.42

SECONDARY outcome

Timeframe: Within 20 minutes of study drug administration

Population: Data not collected (unable to obtain blood specimens at the time of tone scores)

Data were not collected. This measure required blood specimens to be obtained at the time of tone scores and this was not done.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: Calculated at conclusion of operating room case

Population: Pre=specified subgroup analysis, excluded cases of documented nonatonic bleeding (mostly due to hysterotomy extension, present in 21 participants allocated to calcium and 20 participants allocated to placebo).

Pre-specified subgroup analysis of primary outcome: Because the proposed mechanism of calcium action-improving uterine contractility-was not expected to improve bleeding from causes such as hysterotomy extension or arterial bleeding, the trial was powered for a prespecified subgroup analysis excluding patients with nonatonic blood loss documented in the surgeon's operative report. Documented nonatonic bleeding was defined as presence in the surgeon's operative report narrative of any of the following: hysterotomy extension, hysterotomy types other than low transverse (eg classical, T- or J-shaped), invasive or abnormally adherent placenta, placental abruption, uterine rupture, bleeding from leiomyomas, grade 3 or 4 vaginal lacerations, or cervical lacerations.

Outcome measures

Outcome measures
Measure
Calcium Chloride
n=39 Participants
1 gram of calcium chloride in total volume 60mL with sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Saline Placebo
n=40 Participants
60mL sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Quantitative Blood Loss, Subgroup Quantitative Blood Loss (QBL, mL), Excluding Cases of Documented Non-atonic Bleeding
759 milliliters
Interval 592.0 to 912.0
922 milliliters
Interval 754.0 to 1193.0

Adverse Events

Calcium Chloride

Serious events: 0 serious events
Other events: 23 other events
Deaths: 0 deaths

Saline Placebo

Serious events: 0 serious events
Other events: 25 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Calcium Chloride
n=60 participants at risk
1 gram of calcium chloride in total volume 60mL with sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Saline Placebo
n=60 participants at risk
60mL sterile saline, delivered over 10 minute controlled infusion at a constant rate (360mL/hour) beginning 2 minutes after fetal delivery and 1 minute after delayed cord clamp.
Gastrointestinal disorders
New or subjective worsening in nausea
30.0%
18/60 • Number of events 18 • Day of cesarean delivery (and study drug administration). Adverse events were assessed formally at the conclusion of the operating room course prior to transport to the recovery unit. The clinical anesthesiologist discussed all possible side effects with the patient prior to filling out a form. (Anesthesiologist and patient blinded to allocation).
30.0%
18/60 • Number of events 18 • Day of cesarean delivery (and study drug administration). Adverse events were assessed formally at the conclusion of the operating room course prior to transport to the recovery unit. The clinical anesthesiologist discussed all possible side effects with the patient prior to filling out a form. (Anesthesiologist and patient blinded to allocation).
Gastrointestinal disorders
New or increased vomiting
20.0%
12/60 • Number of events 12 • Day of cesarean delivery (and study drug administration). Adverse events were assessed formally at the conclusion of the operating room course prior to transport to the recovery unit. The clinical anesthesiologist discussed all possible side effects with the patient prior to filling out a form. (Anesthesiologist and patient blinded to allocation).
18.3%
11/60 • Number of events 11 • Day of cesarean delivery (and study drug administration). Adverse events were assessed formally at the conclusion of the operating room course prior to transport to the recovery unit. The clinical anesthesiologist discussed all possible side effects with the patient prior to filling out a form. (Anesthesiologist and patient blinded to allocation).
Skin and subcutaneous tissue disorders
Intravenous line pain
1.7%
1/60 • Number of events 1 • Day of cesarean delivery (and study drug administration). Adverse events were assessed formally at the conclusion of the operating room course prior to transport to the recovery unit. The clinical anesthesiologist discussed all possible side effects with the patient prior to filling out a form. (Anesthesiologist and patient blinded to allocation).
5.0%
3/60 • Number of events 3 • Day of cesarean delivery (and study drug administration). Adverse events were assessed formally at the conclusion of the operating room course prior to transport to the recovery unit. The clinical anesthesiologist discussed all possible side effects with the patient prior to filling out a form. (Anesthesiologist and patient blinded to allocation).
Skin and subcutaneous tissue disorders
Flushing
0.00%
0/60 • Day of cesarean delivery (and study drug administration). Adverse events were assessed formally at the conclusion of the operating room course prior to transport to the recovery unit. The clinical anesthesiologist discussed all possible side effects with the patient prior to filling out a form. (Anesthesiologist and patient blinded to allocation).
10.0%
6/60 • Number of events 6 • Day of cesarean delivery (and study drug administration). Adverse events were assessed formally at the conclusion of the operating room course prior to transport to the recovery unit. The clinical anesthesiologist discussed all possible side effects with the patient prior to filling out a form. (Anesthesiologist and patient blinded to allocation).
Cardiac disorders
Change in heart rate
1.7%
1/60 • Number of events 1 • Day of cesarean delivery (and study drug administration). Adverse events were assessed formally at the conclusion of the operating room course prior to transport to the recovery unit. The clinical anesthesiologist discussed all possible side effects with the patient prior to filling out a form. (Anesthesiologist and patient blinded to allocation).
10.0%
6/60 • Number of events 6 • Day of cesarean delivery (and study drug administration). Adverse events were assessed formally at the conclusion of the operating room course prior to transport to the recovery unit. The clinical anesthesiologist discussed all possible side effects with the patient prior to filling out a form. (Anesthesiologist and patient blinded to allocation).
Cardiac disorders
Severe range hypertension
0.00%
0/60 • Day of cesarean delivery (and study drug administration). Adverse events were assessed formally at the conclusion of the operating room course prior to transport to the recovery unit. The clinical anesthesiologist discussed all possible side effects with the patient prior to filling out a form. (Anesthesiologist and patient blinded to allocation).
1.7%
1/60 • Number of events 1 • Day of cesarean delivery (and study drug administration). Adverse events were assessed formally at the conclusion of the operating room course prior to transport to the recovery unit. The clinical anesthesiologist discussed all possible side effects with the patient prior to filling out a form. (Anesthesiologist and patient blinded to allocation).
Nervous system disorders
Abnormal tastes or sensations
0.00%
0/60 • Day of cesarean delivery (and study drug administration). Adverse events were assessed formally at the conclusion of the operating room course prior to transport to the recovery unit. The clinical anesthesiologist discussed all possible side effects with the patient prior to filling out a form. (Anesthesiologist and patient blinded to allocation).
3.3%
2/60 • Number of events 2 • Day of cesarean delivery (and study drug administration). Adverse events were assessed formally at the conclusion of the operating room course prior to transport to the recovery unit. The clinical anesthesiologist discussed all possible side effects with the patient prior to filling out a form. (Anesthesiologist and patient blinded to allocation).

Additional Information

Dr. Jessica Ansari

Stanford

Phone: 650-723-5349

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place